



## **OvaGene Oncology Selected as Best Emerging Company by West Coast Wall Street Conference**

FOR IMMEDIATE RELEASE

Irvine, Calif/ November 29, 2011-- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that the prestigious West Coast Wall Street Conference (WCWSC) has recognized OvaGene with the "Best California Company for 2011" award. The award was presented to OvaGene at November San Diego Investment Conference (SDIC) Ceremony.

The San Diego Investment Conference (SDIC) evaluated many California companies for this award and ultimately chose OvaGene as the recipient of this honor. The award winner was chosen based on the West Coast Wall Street Conference stringent "criteria of excellence" carefully determined by the SDIC management team, advisory board, and a team of analysts from over 60 companies nationwide. OvaGene was presented with the Best California Company for 2011 award based on strong senior management, directors and officers, contribution to society, strong near term outlook and significant achievements in raising capital.

"It is a great honor to be recognized as the Best California Company for 2011", stated Frank Kiesner, J.D., CEO and Founder of OvaGene Oncology. "This recognition further validates the reputation of OvaGene Oncology as an innovative, high quality molecular diagnostic start-up company with a strong, experienced, and dedicated management team diligently working towards advancing gynecologic cancer patient care and improving patient outcomes with novel and proprietary diagnostics."

OvaGene is seeking additional investment for the commercialization and future market expansion for its molecular gynecologic cancer diagnostic assays. OvaGene has a rich pipeline of both proprietary and non-proprietary diagnostic products under development over the next 5 -7 years. Early capital investment in the company will accelerate research/commercialization efforts and fast-track profitability.

### **About OvaGene Oncology**

OvaGene Oncology is a molecular diagnostics company, located in Orange County California, dedicated to improving cancer care and outcomes for gynecologic cancer patients through the development of novel gene-based assays. The company plans to offer proprietary and non-proprietary molecular diagnostic assays to assist physicians in the prognosis of gynecologic cancers as well as therapy selection, including radiation and chemotherapy. There are over 11,000 cases of cervical cancer, 25,000 cases of ovarian cancer and 42,000 cases of endometrial cancer diagnosed each year in the United States. The total market for OvaGene's genomic assays is over 80,000 gynecologic cancer cases diagnosed annually. Please visit our website at [www.ovagene.com](http://www.ovagene.com) for more information about our company.

### **About The San Diego Investment Conference**

The San Diego Investment Conference ("SDIC") was formed to help select companies share information and present investment opportunities. The SDIC assists small to mid-sized emerging-growth public and private companies in gaining exposure and creating funding awareness. SDIC conferences are intended to provide FINRA broker/dealers, investment bankers, investment advisors, analysts, financial managers, fund managers, institutions, media and accredited investors with a forum for networking and communication. Our board of directors and advisory board are renowned nationally in small cap investment banking as well as investment relations conferences with over 50 years of combined experience Please visit [www.sandiegoinvestmentconference.com](http://www.sandiegoinvestmentconference.com) for more information.

###

Contact:

OvaGene Oncology

Jay Coonan, M.D.

Executive Vice President, Strategy and Business Development

e-mail: [jcoonan@ovagene.com](mailto:jcoonan@ovagene.com)

Phone: 480-544 9257